Dr. Ellen W. Friedman, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (1970)
- Years since graduation
- 56
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 112
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1970Medical school: New York University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
NY license 108972
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Montefiore Medical Center Bronx, NY
Medical groups
- Montefiore Medical Center (2,820 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 112
- Services billed
- 1,711
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 50 | 35 |
| Established patient office or other outpatient visit, 20-29 minutes | 37 | 28 |
| Blood smear interpretation by physician with written report | 17 | 15 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 13 | 13 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | 13 |
| Telephone or internet assessment with verbal and written report by consulting physician, 21-30 minutes | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydroxyurea Other prescribers in Bronx, NY | 16 |
| Tasigna (nilotinib hcl) | 13 |
| Jakafi (ruxolitinib phosphate) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 11 payments worth $1,745 in total to this clinician.
| Agios Pharmaceuticals, Inc. | $1,559 |
|---|---|
| Novo Nordisk Inc | $125 |
| Medtronic, Inc. | $41.07 |
| Genetix Biotherapeutics Inc | $20.52 |
| Travel and Lodging | $1,508 |
|---|---|
| Food and Beverage | $238 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Agios Pharmaceuticals, Inc. Oct 19, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Boston, MA | $750 |
| Agios Pharmaceuticals, Inc. Oct 19, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Boston, MA | $349 |
| Agios Pharmaceuticals, Inc. Oct 20, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Boston, MA | $178 |
| Agios Pharmaceuticals, Inc. Oct 19, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Boston, MA | $157 |
| Agios Pharmaceuticals, Inc. Oct 19, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Boston, MA | $36.85 |
| Agios Pharmaceuticals, Inc. Oct 20, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Boston, MA | $36.85 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $84,775 in research payments for these studies, mostly to the institutions running them.
- Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Csl Behring · Recruiting · NCT06699849 - A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose- Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease
Agios Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.